Evonik Evonik

X
[{"orgOrder":0,"company":"Terragenx","sponsor":"Novo Integrated Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Terragenx

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Novo has acquired the intellectual property for iodine in an aqueous form that can be safely ingested and has been proven to kill viruses, bacteria and protozoa when sprayed onto your mucous membranes, the entry points for various airborne viruses.

            Lead Product(s): Iodine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Iodine

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novo Integrated Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition November 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY